Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information [1] Group 1: Company Information - Tandem Diabetes Care issued a press release on August 7, 2025, regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3] - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3] Group 2: Legal Actions - Rosen Law Firm is preparing a class action lawsuit to seek recovery of investor losses for those who purchased Tandem Diabetes Care securities, with no out-of-pocket fees for participants through a contingency fee arrangement [2] - Investors interested in joining the class action can submit their information through the Rosen Law Firm's website or contact them directly [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and consistently ranking in the top 4 for securities class action settlements since 2013 [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4]

NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Tandem Diabetes Care securities you may be entitled to compensation without payment of any out of pocket fees or costs ...